全文获取类型
收费全文 | 3385篇 |
免费 | 191篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 58篇 |
妇产科学 | 55篇 |
基础医学 | 617篇 |
口腔科学 | 94篇 |
临床医学 | 234篇 |
内科学 | 792篇 |
皮肤病学 | 44篇 |
神经病学 | 389篇 |
特种医学 | 71篇 |
外科学 | 389篇 |
综合类 | 38篇 |
一般理论 | 2篇 |
预防医学 | 198篇 |
眼科学 | 12篇 |
药学 | 215篇 |
中国医学 | 10篇 |
肿瘤学 | 343篇 |
出版年
2023年 | 10篇 |
2022年 | 17篇 |
2021年 | 49篇 |
2020年 | 27篇 |
2019年 | 55篇 |
2018年 | 70篇 |
2017年 | 40篇 |
2016年 | 45篇 |
2015年 | 79篇 |
2014年 | 94篇 |
2013年 | 139篇 |
2012年 | 182篇 |
2011年 | 222篇 |
2010年 | 113篇 |
2009年 | 132篇 |
2008年 | 192篇 |
2007年 | 249篇 |
2006年 | 229篇 |
2005年 | 301篇 |
2004年 | 260篇 |
2003年 | 234篇 |
2002年 | 249篇 |
2001年 | 48篇 |
2000年 | 37篇 |
1999年 | 41篇 |
1998年 | 51篇 |
1997年 | 36篇 |
1996年 | 24篇 |
1995年 | 31篇 |
1994年 | 21篇 |
1993年 | 18篇 |
1992年 | 20篇 |
1991年 | 26篇 |
1990年 | 24篇 |
1989年 | 19篇 |
1988年 | 16篇 |
1987年 | 23篇 |
1986年 | 19篇 |
1985年 | 15篇 |
1984年 | 16篇 |
1983年 | 13篇 |
1982年 | 11篇 |
1981年 | 11篇 |
1980年 | 16篇 |
1979年 | 15篇 |
1978年 | 8篇 |
1977年 | 13篇 |
1976年 | 5篇 |
1974年 | 7篇 |
1972年 | 5篇 |
排序方式: 共有3594条查询结果,搜索用时 15 毫秒
51.
A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States) 总被引:3,自引:0,他引:3
Susan E. Hankinson Graham A. Colditz JoAnn E. Manson Walter C. Willett David J. Hunter Meir J. Stampfer Frank E. Speizer 《Cancer causes & control : CCC》1997,8(1):65-72
Results of previous epidemiologic studies have provided reassurance that there is little, if any, increase in risk of breast cancer with oral contraceptive (OC) use in general. However, in several studies, an increased risk of breast cancer has been observed in two subgroups, young women who used OCs for extended durations and in women who used OCs prior to a first-term pregnancy. We evaluated these relationships using data from the ongoing Nurses' Health Study cohort (United States). We documented 3,383 cases of breast cancer from 1976 to 1992 among 1.6 million person-years of follow-up. We observed no overall relationship between duration of OC use and breast cancer risk, even among women who reported using OCs for 10 or more years (multivariate relative risk [RR]=1.11, 95 percent confidence interval [CI]=0.94-1.32). Among women less than 45 years of age, the multivariate RR for using OCs for 10 or more years was 1.07 (CI=0.70-1.65) compared with never-users. The risk associated with five or more years of OC use prior to a first full-term pregnancy compared with never-use was 0.96 (CI=0.65-1.43). Among women less than 45 years of age, we observed no evidence of an increased risk with OC use before a first full-term pregnancy (use for five or more years: RR=0.57, CI=0.24-1.31). Because of the age distribution of our cohort, we were unable to evaluate these relationships among women less than 40 years of age. Our study provides considerable evidence that long-term past OC use, either overall or prior to a first full-term pregnancy, does not result in any appreciable increase in breast cancer risk in women over 40 years of age. 相似文献
52.
Anthony D Harris Yehuda Carmeli Matthew H Samore Keith S Kaye Eli Perencevich 《Infection control and hospital epidemiology》2005,26(4):342-345
BACKGROUND: Case-control studies often analyze risk factors for antibiotic resistance. Recently published articles have illustrated that randomly selected control-patients may be preferable to those with the susceptible phenotype of the organism. A possible methodologic problem with randomly selected control-patients is potential bias due to control group misclassification. This occurs if some control-patients did not have clinical cultures performed and thus might have been unidentified case-patients. If this bias exists, these studies might be expected to report lower odds ratios (ORs) because control-patients would be more like case-patients. OBJECTIVE: To analyze potential biases that might arise due to control group misclassification and potentially larger selection biases that may be introduced if control-patients are required to have at least one clinical culture. PATIENTS: One hundred twenty case-patients, 770 control-patients in group 1, and 510 control-patients in group 2. METHODS: Two case-control studies. Case-patients had clinical cultures positive for imipenem-resistant Pseudomonas aeruginosa. The first group of control-patients were random. The second group of control-patients were identical to those in group 1 except being required to have at least one clinical culture. RESULTS: Univariate analyses showed higher ORs for case-patients versus control-patients in group 1 (imipenem [OR, 12.5], piperacillin-tazobactam [OR, 3.7], and vancomycin [OR, 4.7]) as compared with case-patients versus control-patients in group 2 (imipenem [OR, 8.0], piperacillin-tazobactam [OR, 2.5], and vancomycin [OR, 3.0]). CONCLUSION: Requiring control-patients to have at least one clinical culture introduces a selection bias likely because it eliminates patients with less severe illness. 相似文献
53.
Keith S Kaye Anthony D Harris Matthew Samore Yehuda Carmeli 《Infection control and hospital epidemiology》2005,26(4):346-351
OBJECTIVE: There are significant limitations of the standard case-control study design for identifying risk factors for resistant organisms. The objective of this study was to develop a study design to overcome these limitations. DESIGN: Theoretical analysis of different types of study designs that can be used in risk factor studies for resistant organisms. RESULTS: We developed the case-case-control study design, which uses two separate case-control analyses within a single study. The first analysis compares patients infected with resistant bacteria (resistant cases) with control-patients without infection caused by the target organism, who are therefore representative of the source population; and the second analysis compares patients infected with the susceptible phenotype of the target organism (susceptible cases) with the same control-patients without infection caused by the target organism. These two analyses provide risk models for (1) isolation of the resistant phenotype of the target organism as compared with the source population and (2) isolation of the susceptible phenotype of the organism as compared with the source population. When these two risk models are compared and contrasted, risk factors specifically associated with isolation of the resistant phenotype can be identified. CONCLUSIONS: The case-case-control study design is an effective method for identifying risk factors for antimicrobial-resistant pathogens. Although the case-case-control study design has limitations, it is, in our opinion, more informative and less flawed than the standard case-control study design. 相似文献
54.
Daniella Amital Leah Fostick Yehuda Sasson Seth Kindler Howard Amital Joseph Zohar 《European neuropsychopharmacology》2005,15(3):279-282
BACKGROUND: Several lines of evidence point to serotonergic abnormalities in patients with panic disorder (PD). Our goal was to further examine central serotonergic function in panic patients using autonomic and subjective responses to the postsynaptic serotonin 5-HT1D receptor agonist Sumatriptan. METHOD: Using a double-blind, randomized, placebo-controlled design, we assessed autonomic and subjective responses to oral Sumatriptan (100 mg) and placebo in 15 patients with PD, free of medication. Subjective responses were measured using the Hamilton Anxiety Rating Scale (HAM-A), National Institute of Mental Health Anxiety Scale (NIMHA), a modified version of the Panic Symptom Inventory (PI), Hamilton Depression Rating Scale (HAM-D), and Montgomery-Asberg Depression Rating Scale (MADRS). RESULTS: PD patients exhibited significantly enhanced autonomic and subjective responses following challenge with Sumatriptan. We observed an increased pulse rate and augmentation of various parameters measured on different anxiety scales. A constant inclination of aggravation of the measured parameters was detected during the hour post challenge. CONCLUSION: Oral administration of Sumatriptan, a 5-HT1D agonist, has been associated with an anxiogenic effect in PD patients. 相似文献
55.
56.
Therapeutic approaches for autoimmune diseases are primarily based on suppressive measures that down regulate an over productive immune system. The increasing availability of modern biological therapies has advanced the ability to target and to neutralize essential components of the immune response without experiencing the hazardous adverse effects caused by the traditional immunosuppressants. One of the noticeable examples of this approach is the increasing use of high-dose intravenous immunoglobulin (IVIg). IVIg mechanisms include modulating function of Fc receptors, interference with complement activation and cytokine network, provision of anti-idiotypic antibodies, regulation of cell growth, and effects on of T and B cells. In this review we gather existing information regarding IVIg mechanisms of action, clinical applications and its effects on various conditions. 相似文献
57.
58.
Dimitrios P. Bogdanos Daniel S. Smyk Pietro Invernizzi Eirini I. Rigopoulou Miri Blank Shideh Pouria Yehuda Shoenfeld 《Autoimmunity reviews》2013,12(7):726-740
The “exposome” is a term recently used to describe all environmental factors, both exogenous and endogenous, which we are exposed to in a lifetime. It represents an important tool in the study of autoimmunity, complementing classical immunological research tools and cutting-edge genome wide association studies (GWAS). Recently, environmental wide association studies (EWAS) investigated the effect of environment in the development of diseases. Environmental triggers are largely subdivided into infectious and non-infectious agents. In this review, we introduce the concept of the “infectome”, which is the part of the exposome referring to the collection of an individual's exposures to infectious agents. The infectome directly relates to geoepidemiological, serological and molecular evidence of the co-occurrence of several infectious agents associated with autoimmune diseases that may provide hints for the triggering factors responsible for the pathogenesis of autoimmunity. We discuss the implications that the investigation of the infectome may have for the understanding of microbial/host interactions in autoimmune diseases with long, pre-clinical phases. It may also contribute to the concept of the human body as a superorganism where the microbiome is part of the whole organism, as can be seen with mitochondria which existed as microbes prior to becoming organelles in eukaryotic cells of multicellular organisms over time. A similar argument can now be made in regard to normal intestinal flora, living in symbiosis within the host. We also provide practical examples as to how we can characterise and measure the totality of a disease-specific infectome, based on the experimental approaches employed from the “immunome” and “microbiome” projects. 相似文献
59.
60.
David Bassan Yosi Meir Gozlan Adi Sharbi-Yunger Esther Tzehoval Lea Eisenbach 《International journal of cancer. Journal international du cancer》2019,145(10):2816-2826
Adoptive transfer of T cells that have been genetically modified to express an antitumor T-cell receptor (TCR) is a potent immunotherapy, but only if TCR avidity is sufficiently high. Endogenous TCRs specific to shared (self) tumor-associated antigens (TAAs) have low affinity due to central tolerance. Therefore, for effective therapy, anti-TAA TCRs with higher and optimal avidity must be generated. Here, we describe a new in vitro system for directed evolution of TCR avidity using somatic hypermutation (SHM), a mechanism used in nature by B cells for antibody optimization. We identified 44 point mutations to the Pmel-1 TCR, specific for the H-2Db-gp10025-33 melanoma antigen. Primary T cells transduced with TCRs containing two or three of these mutations had enhanced activity in vitro. Furthermore, the triple-mutant TCR improved in vivo therapy of tumor-bearing mice, which exhibited improved survival, smaller tumors and delayed or no relapse. TCR avidity maturation by SHM may be an effective strategy to improve cancer immunotherapy. 相似文献